News : Press Release

Salius Pharma Reveals Vision 2030: A Roadmap for Global Health Innovation Under the Resolute Leadership of Mr. A.K. Patra

Mumbai, July 30, 2025

Salius Pharma, a rapidly expanding international pharmaceutical and healthcare leader, has unveiled its Vision 2030 — a bold strategic roadmap focused on revolutionizing global healthcare access, advancing high-value APIs, and strengthening its presence in emerging markets. The initiative is spearheaded by the visionary leadership of Mr. A.K. Patra, Founder and Managing Director of Salius Pharma.

With a solid track record of growth, regulatory compliance, and innovation, Vision 2030 outlines an ambitious course for the next five years, driven by the principles of affordability, accessibility, and research-led innovation.

Key Pillars of Vision 2030

1. Expansion in High-Growth Markets

Salius Pharma aims to deepen its footprint across Africa, Latin America, and Southeast Asia, with a strong focus on therapeutic areas such as dermatology, infectious diseases, and chronic care APIs. Countries like Kenya, Nigeria, Brazil, Vietnam, and Egypt are among its top strategic priorities.

2. Leadership in Niche APIs

Already a leading Indian supplier of Selenium Sulfide, Salius Pharma is poised to become a global leader in specialty APIs and intermediates, including antifungals, antiparasitics, and novel nutraceutical molecules.

3. R&D and Sustainability Investments

By 2028, the company plans to double its investment in R&D, with the establishment of new research centers in India and Europe. Sustainability will also be a core focus, with initiatives in green chemistry and eco-friendly manufacturing practices.

4. Affordable Generics for Global Health Equity

Staying true to its mission of delivering affordable, high-quality healthcare, Salius Pharma aims to launch over 50 new generic molecules by 2030, targeting underserved therapeutic needs in low- and middle-income countries.

5. Digitalization & API Supply Chain Optimization

Salius will implement a digital-first strategy to streamline regulatory compliance, enhance customer support, and strengthen its B2B marketplace presence.

Focus Areas of Expansion

Targeted API Supply:

Salius Pharma will increase the supply of essential APIs, including Selenium Sulfide, Cefixime Trihydrate, Metformin Hydrochloride, Atorvastatin Calcium, Metronidazole, Albendazole, and Ivermectin, which are critical to the treatment of dermatological infections, parasitic diseases, and fungal conditions prevalent across the region.

Media Contact:

Salius Pharma Communications Team
 Email: info@saliuspharma.com

 Website: https://saliuspharma.com